Aurobindo Pharma Gets USFDA Approval for Generic Cancer Drug
By Rediff Money Desk, New Delhi Dec 05, 2024 16:30
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities, has received USFDA approval to market Pazopanib Tablets (200 mg) in the US. The drug is therapeutically equivalent to Novartis' Votrient tablets and is expected to launch in Q4FY25.
New Delhi, Dec 5 (PTI) Aurobindo Pharma on Thursday said its subsidiary has received approval from the US health regulator to market a cancer treatment medication in the US.
Eugia Pharma Specialities, a wholly-owned unit of the company, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Pazopanib Tablets (200 mg) in the US market, the Hyderabad-based drug maker said in a regulatory filing.
The company's product is therapeutically equivalent to Novartis Pharmaceuticals Corporation's Votrient tablets (200 mg), it added.
The product is expected to be launched in Q4FY25, the drug maker said.
According to IQVIA data, the product has an estimated market size of USD 106 million for the 12-month period ended October 2024.
Pazopanib Tablets, 200 mg are indicated for the treatment of adults with advanced renal cell carcinoma and advanced soft tissue sarcoma who have received prior chemotherapy.
Shares of Aurobindo Pharma on Thursday ended 0.98 per cent lower at Rs 1,245.70 apiece on the BSE.
Eugia Pharma Specialities, a wholly-owned unit of the company, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Pazopanib Tablets (200 mg) in the US market, the Hyderabad-based drug maker said in a regulatory filing.
The company's product is therapeutically equivalent to Novartis Pharmaceuticals Corporation's Votrient tablets (200 mg), it added.
The product is expected to be launched in Q4FY25, the drug maker said.
According to IQVIA data, the product has an estimated market size of USD 106 million for the 12-month period ended October 2024.
Pazopanib Tablets, 200 mg are indicated for the treatment of adults with advanced renal cell carcinoma and advanced soft tissue sarcoma who have received prior chemotherapy.
Shares of Aurobindo Pharma on Thursday ended 0.98 per cent lower at Rs 1,245.70 apiece on the BSE.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Kretto Syscon
- 1.02 (+ 4.08)
- 66881006
- Shree Securities
- 0.45 (+ 12.50)
- 60278969
- Mishtann Foods L
- 9.67 ( -1.73)
- 59217815
- Vodafone Idea L
- 7.87 ( -1.99)
- 45227161
- YES Bank Ltd.
- 21.21 ( -1.71)
- 26456481
MORE NEWS
Dish TV Shareholders Reject Appointment of Ind...
Dish TV shareholders have rejected the proposal to appoint two independent directors,...
India Needs Investment in Roads, Ports, Energy:...
Veteran banker KV Kamath stresses the need for increased investment in roads, ports,...
IGI IPO: Blackstone-Backed Gem Firm Raises Rs...
International Gemmological Institute (IGI) has raised Rs 1,900 crore from anchor...